Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Perioperative Nivolumab Plus Chemotherapy Improves EFS in Resectable NSCLC

September 22nd 2023

Neoadjuvant treatment with nivolumab plus platinum-based chemotherapy, followed by surgery and adjuvant nivolumab monotherapy, generated a statistically significant and clinically meaningful improvement in event-free survival vs neoadjuvant chemotherapy plus placebo, followed by surgery and adjuvant placebo, in patients with resectable stage IIA to IIIB non–small cell lung cancer.

The Evolving Treatment Landscape of Small Cell Lung Cancer

September 22nd 2023

Closing out their program on small cell lung cancer management, Laurent Greiller, MD, and Christian Grohé, MD, highlight what excites them most about the evolving treatment paradigm.

Dr Liu on the Frequency of Activating ERBB2 and ERBB3 Alterations in NSCLC

September 22nd 2023

Dazhi Liu, PharmD, MS, BCOP, discusses findings from a real-world analysis of the frequency of ERBB2 and ERBB3 alterations in patients with non–small cell lung cancer and the efficacy of liquid vs tissue biopsies for detecting these alterations.

Ifinatamab Deruxtecan Demonstrates Robust Efficacy, Acceptable Safety in SCLC

September 21st 2023

Melissa L. Johnson, MD, spotlights the early-phase investigation of ifinatamab deruxtecan in advanced solid tumors, discusses the efficacy and safety of the agent in patients with small cell lung cancer, and emphasizes how results from a subgroup analysis support its continued investigation.

Dr Liu on the 5-Year OS Data With Atezolizumab and Chemotherapy in ES-SCLC

September 20th 2023

Stephen V. Liu, MD, discusses the 5-year overall survival data with atezolizumab and chemotherapy in patients with extensive-stage small cell lung cancer.

Dr Loghavi on the Expansion of Genetically-Defined Subtypes in AML

September 20th 2023

Sanam Loghavi, MD, discusses the expansion of genetically-defined categories of acute myeloid leukemia in the World Health Organization classification, and how this affects the diagnosis of patients in this space.

Thoracic Clinical Expert Looks at Optimal Ways to Translate Data Into Practice

September 20th 2023

As oncogene-driven therapies move into clinical practice, it is paramount that clinicians have the tools and understanding to integrate the latest evidence for the appropriate treatment of patients with lung cancer.

Emerging Treatment Options for Patients with NSCLC with ALK Rearrangements

September 19th 2023

Experts on non–small cell lung cancer discuss recent data on brigatinib and lorlatinib for the treatment of patients with ALK rearrangements.

Is There a Role for Immunotherapy in Patients with KRAS G12C-Mutant NSCLC and STK11 or KEAP1 Co-Mutations?

September 19th 2023

Luis Raez, MD, offers insights on how co-mutations in STK11 or KEAP1 impact the use of immunotherapies in KRAS G12C–mutant non–small cell lung cancer.

Dr Luo on Optimal Initial Chemotherapy Regimens in NUT Carcinoma

September 18th 2023

Jia Luo, MD, discusses a retrospective analysis of initial chemotherapy regimens for the treatment of patients with locally advanced and metastatic NUT carcinoma, which was presented at the 2023 IASLC World Conference on Lung Cancer.

Trastuzumab Deruxtecan Receives CHMP Recommendation for Approval in HER2-Mutant NSCLC

September 15th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended fam-trastuzumab deruxtecan-nxki for use as a single agent in adult patients with HER2-mutated, advanced non–small cell lung cancer who require systemic treatment after platinum-based chemotherapy with or without immunotherapy.

Adjuvant Pembrolizumab Receives Positive CHMP Opinion for High-Risk NSCLC After Resection and Chemo

September 15th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of pembrolizumab as adjuvant treatment for adult patients with non–small cell lung cancer who are at high risk of recurrence following complete resection and platinum-based chemotherapy.

Clinical Data With Lurbinectedin in Small Cell Lung Cancer

September 15th 2023

Key opinion leaders share a focused discussion on lurbinectedin and its evolving role in small cell lung cancer following frontline therapy.

Overview of Second-Line Treatment Options in SCLC

September 15th 2023

Expert oncologists Laurent Greiller, MD, and Christian Grohé, MD, reflect on the current state of second-line treatment options for patients with small cell lung cancer.

Subcutaneous Amivantamab Is Associated With Increased Tolerability in Solid Tumors

September 14th 2023

Anna Minchom, MB BCh, MRCP, MD, discusses the need to develop an amivantamab administration method that decreases the likelihood of infusion-related reactions in patients with solid tumors, revealed the RP2D of subcutaneous amivantamab that was determined in the PALOMA trial, and emphasized potential future directions with this agent.

Lung Cancer Experts Detail Challenges of Cisplatin/Carboplatin Shortages

September 13th 2023

Experts discuss the challenges of the ongoing cisplatin and carboplatin shortages in the United States and detail how they are adapting in their practices.

Dr Leighl on Amivantamab in Advanced NSCLC With MET Exon 14 Skipping Mutations

September 12th 2023

Natasha B. Leighl, BSc, MMSc, MD, discusses efficacy findings with the EGFR/MET inhibitor amivantamab in patients with advanced non–small cell lung cancer harboring MET exon 14 skipping mutations.

Dr Leal on a PD-L1 Subgroup Analysis of the LUNAR Trial in mNSCLC

September 12th 2023

Ticiana Leal, MD, discusses the rationale for and findings from a PD-L1 subgroup analysis of the phase 3 LUNAR trial in patients with metastatic non–small cell lung cancer.

Adagrasib for Patients with KRAS G12C–Mutant NSCLC

September 12th 2023

Joshua K. Sabari, MD, discusses adagrasib as a treatment of patients with NSCLC with KRAS G12C mutations, and provides insight on treating patients who have progressed on prior KRAS G12C inhibitors.

Sotorasib in the Treatment of KRAS G12C–Mutant NSCLC

September 12th 2023

Expert panelists review the CodeBreaK trials focused on sotorasib in the treatment of patients with KRAS G12C-mutant non–small cell lung cancer.